MariTide

positive negative up down good bad mixed
Biotech

Amgen's ph. 3 MariTide study will ramp up dosing to quell nausea

The company noted high rates of discontinuation due to gastrointestinal events, such as vomiting, in fixed-dose arms of its phase 2 trial.
Zoey Becker Jun 24, 2025 9:59am
boat cutting through water

Amgen’s late-stage obesity trials expected to read out in ‘27

Mar 5, 2025 1:58pm